Biogen
BIIB
951 hedge funds and large institutions have $28B invested in Biogen in 2024 Q1 according to their latest regulatory filings, with 89 funds opening new positions, 302 increasing their positions, 354 reducing their positions, and 145 closing their positions.
8% more capital inflows, than outflows
Capital inflows: $2.2B | Capital outflows: $2.04B
0.27% more ownership
Funds ownership: 89.01% → 89.28% (+0.27%)
0% more call options, than puts
Call options by funds: $303M | Put options by funds: $303M
5% less funds holding
Funds holding: 1,001 → 951 (-50)
15% less repeat investments, than reductions
Existing positions increased: 302 | Existing positions reduced: 354
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
39% less first-time investments, than exits
New positions opened: 89 | Existing positions closed: 145
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$507M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$140M |
| 3 |
Beutel, Goodman & Co
Toronto,
Ontario, Canada
|
+$134M |
| 4 |
Camber Capital Management
Boston,
Massachusetts
|
+$93.7M |
| 5 |
VanEck Associates
New York
|
+$74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$151M |
| 2 |
Carmignac Gestion
Paris,
France
|
-$93.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$89.1M |
| 4 |
JP Morgan Chase
New York
|
-$82.6M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$82.1M |
BIIB Hedge Fund Activity: Q1 2024 in Review
951 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2024, worth a combined $28B — down 16% from $33.4B a quarter earlier.
Sellers outnumbered buyers: 145 funds closed out of BIIB and 89 opened new positions — a net loss of 56 holders — while 354 trimmed existing stakes and 302 added.
The largest buyer was Vanguard Group, adding an estimated $507M. The largest seller was First Trust Advisors, cutting an estimated $151M.
- 951 institutional investors held Biogen (BIIB) as of Q1 2024, down from 1,001 in Q4 2023.
- Funds reported $28B of Biogen stock for Q1 2024, down 16% quarter-over-quarter.
- 89 funds opened new Biogen positions in Q1 2024 and 145 closed out, a net change of -56 holders.
- The largest Biogen buyer in Q1 2024 was Vanguard Group, an estimated $507M added.
- The largest Biogen seller in Q1 2024 was First Trust Advisors, an estimated $151M sold.
Based on aggregated 13F filings for Q1 2024.